ORPHA:98846
Classic Hodgkin lymphoma, lymphocyte-depleted type
Publications
121
52.7th percentile
Trials
5
Interventional, condition-specific
Researchers
553
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0004620
- UMLS:C0152267
- NCIT:C9125
Additional Mondo synonyms (13)
Adult lymphocyte-depleted Classic Hodgkin lymphoma · Hodgkin lymphoma, lymphocyte depletion · Hodgkin's disease, lymphocytic depletion NOS (morphologic abnormality) · Hodgkin's disease, lymphocytic depletion, unspecified site, extranodal and solid organ sites · adult HDLD · adult LDHD · adult lymphocyte depleted Hodgkin lymphoma · adult lymphocyte depleted Hodgkin's lymphoma · adult lymphocyte depleted classical Hodgkin lymphoma · adult lymphocyte depletion Hodgkin's disease · adult lymphocyte-depleted classical Hodgkin lymphoma · classic Hodgkin lymphoma, lymphocyte-depleted type · lymphocyte-depleted classical Hodgkin lymphoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
121 matched papers (48 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
5 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
121
121 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
121 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
48 in the last 10 years · high confidence · 52.7th percentile (publications denominator)
Phrase hits: 121 · MeSH hits: 0
Who's working on it?
553
Distinct author names in 121 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Jaffe ES6 papers · 2019
Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. elainejaffe@nih.gov
Papers in Europe PMC - 02Godfrey VL5 papers · 1995
Biology Division, Oak Ridge National Laboratory, TN 37831-8077.
Papers in Europe PMC - 03Wilkinson JE5 papers · 1995Papers in Europe PMC
- 04Harris NL4 papers · 2016
Department of Pathology, Harvard Medical School and Massachusetts General Hospital, Boston, MA;
Papers in Europe PMC - 05Huang Y3 papers · 2026
Department of Hematology, Baise People's Hospital, Baise, Guangxi, China.
Papers in Europe PMC - 06Isaacson PG3 papers · 2008Papers in Europe PMC
- 07
- 08Campo E2 papers · 2016
Hematopathology Section, Department of Anatomic Pathology, Hospital Clinic, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. elainejaffe@nih.gov
Papers in Europe PMC - 09Chino J2 papers · 2014
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, the University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
Papers in Europe PMC - 10Doche I2 papers · 2021
Department of Dermatology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
5
interventional trials for this specific condition
5 interventional trials matched this specific condition name; none in our sample are currently recruiting. 45 trials are registered for classic Hodgkin lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
5 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 87.9th percentile).
high confidence · 87.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
5 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: classic Hodgkin lymphoma
45
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07572123·NOT YET RECRUITING·Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06190067·RECRUITING·Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Conditions: Relapsed Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma·Matched via name phrase
- NCT07097363·RECRUITING·Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Conditions: B-Cell Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified·Matched via name phrase
- NCT06377540·RECRUITING·MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Conditions: Autologous Stem Cell Transplant · Classic Hodgkin Lymphoma·Matched via name phrase
- NCT07021989·NOT YET RECRUITING·ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma, Adult · Refractory Hodgkin Lymphoma · Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06465446·NOT YET RECRUITING·A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
Conditions: Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06642792·RECRUITING·A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Conditions: Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06170489·RECRUITING·A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Conditions: Hodgkin Lymphoma·Matched via name phrase
- NCT05955105·RECRUITING·A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Conditions: Head and Neck Cancer · Cervical Cancer · Endometrial Cancer · Triple Negative Breast Cancer·Matched via name phrase
- NCT05039073·RECRUITING·Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Conditions: Recurrent Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06916416·NOT YET RECRUITING·Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma·Matched via name phrase
- NCT05949931·RECRUITING·Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Conditions: Classic Hodgkin Lymphoma·Matched via name phrase
- NCT07275216·RECRUITING·Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Conditions: Classic Hodgkin Lymphoma·Matched via name phrase
- NCT04561206·RECRUITING·Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Conditions: Relapsed Classic Hodgkin Lymphoma·Matched via name phrase
- NCT06745076·RECRUITING·Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
Conditions: Advanced Hodgkin Lymphoma · Classic Hodgkin Lymphoma · Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 · Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Classic Hodgkin lymphoma, lymphocyte-depleted type" OR "Adult lymphocyte-depleted Classic Hodgkin lymphoma" OR "Hodgkin lymphoma, lymphocyte depletion" OR "Hodgkin's disease, lymphocytic depletion NOS (morphologic abnormality)" OR "Hodgkin's disease, lymphocytic depletion, unspecified site, extranodal and solid organ sites" OR "adult HDLD" OR "adult LDHD" OR "adult lymphocyte depleted Hodgkin lymphoma" OR "adult lymphocyte depleted Hodgkin's lymphoma" OR "adult lymphocyte depleted classical Hodgkin lymphoma" OR "adult lymphocyte depletion Hodgkin's disease" OR "adult lymphocyte-depleted classical Hodgkin lymphoma" OR "lymphocyte-depleted classical Hodgkin lymphoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Classic Hodgkin lymphoma, lymphocyte-depleted type" OR "Adult lymphocyte-depleted Classic Hodgkin lymphoma" OR "Hodgkin lymphoma, lymphocyte depletion" OR "Hodgkin's disease, lymphocytic depletion NOS (morphologic abnormality)" OR "Hodgkin's disease, lymphocytic depletion, unspecified site, extranodal and solid organ sites" OR "adult HDLD" OR "adult LDHD" OR "adult lymphocyte depleted Hodgkin lymphoma" OR "adult lymphocyte depleted Hodgkin's lymphoma" OR "adult lymphocyte depleted classical Hodgkin lymphoma" OR "adult lymphocyte depletion Hodgkin's disease" OR "adult lymphocyte-depleted classical Hodgkin lymphoma" OR "lymphocyte-depleted classical Hodgkin lymphoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 5 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"classic Hodgkin lymphoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T05:34:49.156Z
